• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

    9/17/24 11:22:47 AM ET
    $AZN
    $BLTE
    $HCM
    $IH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, September 24 and Wednesday, September 25, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US.

    Representatives from participating companies based in China, France, Hong Kong, Netherlands, Philippines, Portugal, Spain, Switzerland, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies.

    There is no fee for participants to log in, attend live presentations and/or ask questions.

    Pre-registration is suggested. Please register here: www.adr.db.com/dbvic

    September 24 Agenda (US Eastern Standard Time):

    • 8:00 AM: First Pacific Company Ltd ((HKEX: 142, OTC:FPAFY)
    • 8:30 AM: Lotus Technology Inc (NASDAQ:LOT)
    • 9:00 AM: HUTCHMED (China) Limited ((AIM: HCM, NASDAQ:HCM, and HKEX:13))
    • 9:30 AM: iHuman Inc. (NYSE:IH)
    • 10:00 AM: Marks and Spencer ((LSE: MKS, OTC:MAKSY)
    • 10:30 AM: SSE plc ((LSE: SSE, OTC:SSEZY)
    • 11:00 AM: BDO Unibank, Inc ((PSE: BDO, OTC:BDOUY)
    • 11:30 AM: AstraZeneca plc ((LSE: AZN, NASDAQ:AZN)

    September 25 Agenda (US Eastern Standard Time):

    • 8:00 AM: Yiren Digital Ltd (NYSE:YRD)
    • 8:30 AM: KPN ((Euronext Amsterdam: KPN, OTC:KKPNY)
    • 9:00 AM: Viomi Technology Co., Ltd (NASDAQ:VIOT)
    • 9:30 AM: Carrefour S.A. (PARIS:CA, OTC:CRRFY)
    • 10:00 AM: EDP Group ((Euronext Lisbon: EDP, OTC:EDPFY)
    • 10:30 AM: Repsol S.A ((BMAD: REP, OTC:REPYY)
    • 11:00 AM: Belite Bio, Inc  (NASDAQ:BLTE)
    • 11:30 AM: DSM-Firmenich AG ((DSFIR:AEX, OTC:DSFIY)

    The presentations will be available for replay after the Conference.

    In addition to specializing in administering cross-border equity structures such as American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. The Bank offers a broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

    For further information, please contact:

    Dylan Riddle

    Deutsche Bank AG

    Press & Media Relations

    Tel. +12122504982

    Cell. +1(904)3866481

    Email [email protected]

    Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany's leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

    Deutsche Bank is sponsoring the Deutsche Bank Depositary Receipt Investor Conference solely for informational purposes. Deutsche Bank does not prepare, review, approve or edit any presentations, statements, documents or other information or materials, whether in written, electronic or verbal form, provided by any company participating in such conference, and disclaims any responsibility for the accuracy or adequacy of any such information or materials. Deutsche Bank is not promoting, endorsing or recommending any company participating in the conference.

    The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© September 2024 Deutsche Bank AG. All rights reserved.



    Primary Logo

    Get the next $AZN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN
    $BLTE
    $HCM
    $IH

    CompanyDatePrice TargetRatingAnalyst
    HUTCHMED (China) Limited
    $HCM
    5/13/2025Buy → Hold
    HSBC Securities
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    AstraZeneca PLC
    $AZN
    2/12/2025Overweight
    Morgan Stanley
    AstraZeneca PLC
    $AZN
    11/20/2024Sell → Neutral
    UBS
    AstraZeneca PLC
    $AZN
    11/6/2024Sell → Hold
    Deutsche Bank
    AstraZeneca PLC
    $AZN
    9/13/2024Hold → Sell
    Deutsche Bank
    AstraZeneca PLC
    $AZN
    5/30/2024$97.00Buy
    Goldman
    More analyst ratings

    $AZN
    $BLTE
    $HCM
    $IH
    SEC Filings

    View All

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    8/20/25 6:12:04 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 305B2 filed by Lotus Technology Inc.

    305B2 - Lotus Technology Inc. (0001962746) (Filer)

    8/19/25 8:35:17 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    SEC Form 424B5 filed by Lotus Technology Inc.

    424B5 - Lotus Technology Inc. (0001962746) (Filer)

    8/19/25 8:34:07 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    $AZN
    $BLTE
    $HCM
    $IH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HUTCHMED downgraded by HSBC Securities

    HSBC Securities downgraded HUTCHMED from Buy to Hold

    5/13/25 3:20:36 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

    Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

    4/15/25 12:40:56 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca upgraded by UBS

    UBS upgraded AstraZeneca from Neutral to Buy

    2/13/25 8:39:12 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $BLTE
    $HCM
    $IH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) as a first-line treatment in certain non-small cell lung cancer ("NSCLC") patients whose tumors harbor epidermal growth factor receptor ("EGFR") mutation and MET overexpression. The last patient was enrolled on August 18, 2025. This Phase III trial is a blinded, randomized, controlled study in previously untreated patients with locally advanced or metastatic NSCLC with activating EGFR mutations and MET o

    8/19/25 8:00:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lotus Technology Received up to $300 Million Funding Commitment to Advance Business Development and Strengthen Liquidity

    NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus" or the "Company"), a leading global intelligent and luxury mobility provider, announced today that it entered into a securities purchase agreement ("the Transaction") with ATW Partners, a New York-based investment firm that focuses on cutting-edge companies with long-term growth potential, under which the Company agreed to issue and sell convertible notes for up to an aggregate principal amount of $300 million that will be convertible into ordinary shares of the Company in the form of American depositary shares of the Company. Mr. Qingfeng Feng, Chief Executive Officer, commented: "The new funding dem

    8/19/25 8:30:00 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    Lotus Technology to Report Unaudited First Half 2025 Financial Results on August 29, 2025

    NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus" or the "Company") (NASDAQ:LOT), a leading global intelligent and luxury mobility provider, today announced that it will report its unaudited financial results for the first half 2025 on August 29, 2025, before market opening in the United States. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on Friday, August 29, 2025 (14:00 Central European Time / 20:00 China Standard Time on the same day). There will be a live audio webcast and replay available following completion of the call on the Company's investor relations website at https://ir.group-lotus.com/news-events/event

    8/18/25 8:00:00 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    $AZN
    $BLTE
    $HCM
    $IH
    Leadership Updates

    Live Leadership Updates

    View All

    Lotus Technology Announces Management and Board Changes

    NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus" or the "Company") (NASDAQ:LOT), a leading global intelligent and luxury mobility provider, today announced changes to its management team and board of directors. The board of directors of the company (the "Board") has approved the appointment of Mr. Daxue Wang as the Chief Financial Officer ("CFO") of the Company effective April 8, 2025. Mr. Wang is a seasoned executive across corporate and prominent financial institutions, most recently serving as CFO of Radar Auto. Prior to that, Mr. Wang held several executive positions in Zhejiang Kangsheng, Huzhou Moshan Asset Management, Morgan Stanley Securities, ICBC Credi

    4/8/25 4:30:00 PM ET
    $LOT
    Auto Manufacturing
    Industrials

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from March 6, 2025. Mr Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting companies with their stock exchange listings and has been instrumental in completing numerous mergers and acquisitions. After a distinguished career spanning more than three decades, Mr Wong retired as

    3/5/25 5:00:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viomi Technology Co., Ltd Appoints New President of Operations to Promote High-quality Business Development

    GUANGZHOU, China, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ:VIOT), a leading technology company for home water solutions in China, today announced the appointment of Mr. Guang Wu as President of Operations, effective December 4, 2024. In this role, Mr. Wu will focus on driving high-quality business development and enhancing operational efficiency. Mr. Wu brings over 20 years of experience in business development and marketing within the domestic home appliances and home furnishing industry. Prior to joining Viomi, he served as Vice President and General Manager of Domestic Marketing at Sleemon Group. Before that, he managed domestic m

    12/4/24 4:00:00 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    $AZN
    $BLTE
    $HCM
    $IH
    Financials

    Live finance-specific insights

    View All

    Lotus Technology to Report Unaudited First Half 2025 Financial Results on August 29, 2025

    NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus" or the "Company") (NASDAQ:LOT), a leading global intelligent and luxury mobility provider, today announced that it will report its unaudited financial results for the first half 2025 on August 29, 2025, before market opening in the United States. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on Friday, August 29, 2025 (14:00 Central European Time / 20:00 China Standard Time on the same day). There will be a live audio webcast and replay available following completion of the call on the Company's investor relations website at https://ir.group-lotus.com/news-events/event

    8/18/25 8:00:00 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    Yiren Digital to Report Second Quarter 2025 Financial Results on August 21, 2025

    BEIJING, Aug. 14, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital"), an AI-powered platform providing a comprehensive suite of financial services in Asia, announced that it plans to release its unaudited financial results for the second quarter ended June 30, 2025 before U.S. market opens on Thursday, August 21, 2025. Yiren Digital's management will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on August 21, 2025 (or 8:00 p.m. Beijing/Hong Kong Time on August 21, 2025). Participants who wish to join the call should register online in advance of the conference at: https://dpregister.com/sreg/10202094/ffb82a2282 Once registration is completed, participants

    8/14/25 6:15:00 AM ET
    $YRD
    Finance: Consumer Services
    Finance

    AstraZeneca results: H1 and Q2 2025

    Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date AstraZeneca: Revenue and EPS summary   H1 2025 % Change Q2 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 26,670 8 10 13,795 11 10 - Alliance Revenue 1,293 38 38 654 36 35 Product Revenue2 27,963 9 11 14,449 12 11 Collaboration Revenue 82 68 66 8 >2x >2x Total Revenue 28,045 9 11 14,457 12 11

    7/29/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $BLTE
    $HCM
    $IH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viomi Technology Co. Ltd

    SC 13G/A - Viomi Technology Co., Ltd (0001742770) (Subject)

    11/12/24 6:35:53 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    SEC Form SC 13G filed by Lotus Technology Inc.

    SC 13G - Lotus Technology Inc. (0001962746) (Subject)

    11/12/24 6:07:58 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    SEC Form SC 13G filed by Lotus Technology Inc.

    SC 13G - Lotus Technology Inc. (0001962746) (Subject)

    11/8/24 6:04:35 AM ET
    $LOT
    Auto Manufacturing
    Industrials